- Open Access
Fanconi anemia protein FANCD2 inhibits TRF1 polyADP-ribosylation through tankyrase1-dependent manner
- Alex Lyakhovich†1, 2,
- Maria Jose Ramirez†1, 3,
- Andres Castellanos1,
- Maria Castella1, 3, 4,
- Amanda M Simons5,
- Jeffrey D Parvin5, 6 and
- Jordi Surralles1, 3Email author
© Lyakhovich et al; licensee BioMed Central Ltd. 2011
Received: 3 November 2010
Accepted: 12 February 2011
Published: 12 February 2011
Fanconi anemia (FA) is a rare autosomal recessive syndrome characterized by developmental abnormalities, progressive bone marrow failure, and predisposition to cancer. The key FA protein FANCD2 crosstalks with members of DNA damage and repair pathways that also play a role at telomeres. Therefore, we investigated whether FANCD2 has a similar involvement at telomeres.
We reveal that FANCD2 may perform a novel function separate to the FANCD2/BRCA pathway. This function includes FANCD2 interaction with one of the telomere components, the PARP family member tankyrase-1. Moreover, FANCD2 inhibits tankyrase-1 activity in vitro. In turn, FANCD2 deficiency increases the polyADP-ribosylation of telomere binding factor TRF1.
FANCD2 binding and inhibiting tankyrase-1PARsylation at telomeres may provide an additional step within the FA pathway for the regulation of genomic integrity.
Fanconi anemia (FA) is a rare recessive disorder associated with chromosomal fragility, aplastic anemia, congenital abnormalities and a predisposition to cancer [1, 2]. Cells from FA patients exhibit hypersensitivity to DNA cross-linking agents suggesting the role of FA proteins in the repair of damaged DNA [3, 4]. Currently, at least 14 FA genes are known to exist, each of them representing a different FA subtype [5–7]. Although they have very few similarities, the encoded FA proteins cooperate in a common FA/BRCA pathway by forming several complexes, where the activation of a key FA protein FANCD2 (and FANCI) seems to orchestrate the cascade of events in response to DNA damage [8, 9].
FA proteins crosstalk with several proteins involved in both DNA damage response and telomere regulation [10–13]. Telomeres, the ends of chromosomes, consist of TTAGGG tandem repeats (in mammals) forming a T-loop structure and a 3' G-rich single-stranded overhang that invades the telomeric tracts forming a D loop [14–18]. In most human somatic cells telomeres undergo shortening with each cycle of cell division due to what is known as the "end-replication problem" [19, 20]. To prevent such shortening, a specialized enzyme called telomerase serves to maintain telomere length . In normally dividing somatic cells telomerase is insufficiently active to compensate for telomere shortening and telomeres undergo attrition with each round of cell division. In turn, telomeres in cancer cells are maintained either by the activation of telomerase or by the homologous recombination mechanism known as alternative lengthening of telomeres (ALT) [22–24].
Telomeres are capped by a complex of proteins called shelterin, which contains TRF1, TRF2, POT1 and associated proteins including TIN2, TPP1, Rap1 and poly-(ADP-ribose)-polymerase enzymes tankyrase 1 and 2 (TNKS1/2) [23, 25]. TIN2 negatively regulates telomere length by changing the telomeric DNA structure, stabilizing the T-loop and possibly limiting DNA accessibility to telomerase . Conversely, TNKS1 positively regulates telomere length by the polyADP-ribosylation (PARsylation) of TRF1 thus preventing TRF1 from binding to telomeres [26, 27]. Similar regulation occurs through the communication of TRF1 and POT1 [28, 29]. The fact that (i) many telomere-localized and FA proteins were found among DNA repair proteins [30, 31]; (ii) FANCD2 was shown to bind Holliday junction DNA, an intermediate of homologous recombination and stalled replication forks ; and (iii) FA proteins are involved in the ALT mechanism of telomere maintenance [33, 34] prompted us to test for the possible engagement of FANCD2 in telomeres of normal cells.
Here we demonstrate that FANCD2 interacts both with telomeric DNA and TNKS1 in vitro. Moreover, FANCD2 inhibits TNKS1 PARsylation activity and TNKS1-mediated TRF1 PARsylation. Such a novel function of FANCD2 may provide an additional step for maintaining genomic stability.
FANCD2 binds to telomeric DNA in vitro
FANCD2 binds to TNKS1
FANCD2 inhibits TNKS1 and TRF1 PARsylation
Since the main known cellular function of TNKS1 is PARsylation of the telomere repeat binding factor TRF1 that results in detaching TRF1 from telomere complexes [26, 27], we performed an in vitro TRF1/TNKS1 PARP assay in the presence of recombinant FANCD2. Similar to the above data, we observed the FANCD2-dependent inhibition of TRF1 PARsylation (Figure 4B). The presence of double-stranded telomeric DNA only slightly increased the inhibition of TRF1 PARsylation (data not shown). Thus, our results suggest that FANCD2 inhibits the autoPARsylation of TNKS1 and PARsylation of TRF1 in vitro.
FANCD2 affects TRF1 binding to telomeric DNA
While normal FANCD2 activity is evident for maintaining living functions of any cell, it is yet unclear whether the key FA protein FANCD2 may possess biochemical properties other than crosstalk with the FA members upon resolving stalled replication forks. Our current study suggests that FANCD2 may serve a separate role, separate to FA-complex-mediated FANCD2/FANCI monoubiquitinylation. This role includes the inhibition of tankyrase 1-dependent TRF1 PARsylation which, in turn, protects telomeric DNA. We suggest that under normal conditions, FANCD2 safeguards genomic integrity both by inhibiting TNKS1-mediated TRF1 PARsylation and by protecting telomeric DNA through TRF1. TRF1 binding to telomeric DNA is essential for telomere function, whereas PARsylation of TRF1 reduces TRF1 affinity for telomeric DNA.
Recent studies showed that overexpression of TNKS1 in normal human cells results in the downregulation of TRF1, but has no effect on telomere length . In addition, inhibition of TRF1 in normal human (IMR90) cells using TRF1-dominant negative allele had no effect on telomere length . It was reported previously that the knockdown of FANCD2 rapidly causes telomere dysfunction in cells that rely on ALT mechanism . Studies by Fan et al. suggest telomeric localization of FANCD2 in ALT cells and that the transient depletion of FANCD2 or FANCA results in a loss of detectable telomeres in ALT, but not in telomerase-positive cells . Some previous works on telomerase-mediated telomere lengthening and generation of ECS by telomere trimming upon inhibition of TRF1  incited us to examine possible changes in telomere length in our model. However, measurements of telomere length in siRNA FANCD2 depleted primary fibroblasts either using Southern blot analyses of genomic DNA (additional file 1), Q-FISH analyses in cells' metaphase (additional file 2), or Flow-FISH technique in interphase (additional file 3) did not reveal any significant changes. We can not disregard the fact that this short period of the transient depletion of FANCD2 by siRNA may not be sufficient to detect alterations in telomere length. Moreover, several other studies demonstrated telomere attrition in the FA cells of an upstream FA subtype [11, 39–41]. For instance, telomere length was shown to be shorter in 54 FA patient samples, compared to 51 controls . Similarly, a correlation between severe aplastic anemia and the individual annual telomere-shortening rate in peripheral blood mononuclear cells was observed in 71 FA patients . These facts may suggest that telomere shortening may occur in some upstream FA subgroups as a consequence of proliferative stress. The role of FANCD2 binding with TNKS1 and telomeric DNA is still quite intriguing. On the one hand, such binding may affect telomere maintenance by protecting telomeric DNA, in a similar manner to the role of shelterin. On the other hand, FANCD2 functions as a modulator of TNKS1 activity which, in turn, may affect telomere maintenance.
Based on our experiments aimed at justifying the direct link of FANCD2 to changes in telomere length we may conclude that the presence of FANCD2 may only affect telomere stability, but not the length. Moreover, our studies on a variety of human cells do not exclude that FANCD2-dependent telomere alteration also involves other aspects of FANCD2 function. Those aspects could include the role of FANCD2 at replication fork or the recently proposed link between FANCD2 and oxidative damage . Consequently, the TRF1 removal described here can be one of the possible effects of FANCD2 in telomere biology. Another interpretation could be that FANCD2 stabilizes the t-loop structure. Although our data do not demonstrate this possibility, they are highly suggestive due to the following reasons: (i) homologous recombination at t-loop leads to an extra-chromosomal circle in the presence of TRF2 deltaB ; (ii) FANCD2 binds Holliday junction, which might contribute to t-loop stabilization [32, 44], (Giraud-Panis and Gilson, personal communication); (iii) TRF1 contributes to t-loop formation . Overall, our finding of a novel interaction of FANCD2 may contribute to understanding the differences between downstream FA-D2 versus upstream FA groups.
FANCD2 interacts both with telomeric DNA and with telomeric protein TNKS1 in vitro. Moreover, FANCD2 inhibits TNKS1 autoPARsylation and TNKS1-dependent TRF1 PARsylation thus affecting stability but not the length of telomeres. This novel interaction of FANCD2 may provide an additional safeguard role to secure genome integrity.
Cell Lines and Treatment
The following cell lines were used in this study: human transformed fibroblasts PD20 (FANCD2-/-); PD20 cor. (PD20 retrovirally corrected with pMMp-FANCD2 cDNA); PD20 transduced with pMMp-FANCD2/K561R MRC5; HeLa and primary fibroblasts (yoli) All the cell lines were cultured as described previously . Importantly, PD20 cells and variants are SV40 transformed fibroblast and they are telomerase positive, as studied by both RT-PCR of hTETR and with the TRAP assay. 3AB PARP inhibitor (Sigma) was used at 3 mM concentration. Treatment with PARP inhibitor at this concentration did not significantly affect the cell cycle, as measured by flow cytometry (data not shown). The cell cycle was verified by flow cytometry and then analyzed using BD PharMingen FACScan and CellQuest software exactly as described earlier .
Preparation of Human Cell Lysates
Cells were washed with ice-cold PBS and resuspended in the buffer consisting of 20 mM HEPES (pH 7.9), 420 mM KCl, 25% glycerol, 0.1 mM EDTA, 5 mM MgCl2, 0.2% Nonidet P-40, 1 mM dithiothreitol, and a 1:40 volume of protease and phosphatase inhibitor mixture (Sigma) on ice for 30 min. After centrifugation at 12,000 g for 10 min at 4°C, the supernatant was collected as the total cell lysate. Separation on nuclear and cytoplasmic fractions has been performed as described in Bogliolo et al. . PBS-washed nuclear cell pellets were further resuspended in buffer containing 5 mM MgCl2/PBS, 10 mM HEPES (pH 7.9), 10 mM KCl, 20% glycerol, 1 mM dithiothreitol, and a protease inhibitor mixture (Sigma). The pellets were homogenized on ice by sonication, clarified by centrifugation and stored at -20°C for further experiments.
DNA Templates and Foot-Print analyses
Telomere DNA for footprint analysis was constructed by modifying telomere sequences obtained from Dr. Giraud-Panis  by cutting out the right-size fragment from puc19-based pTelo2 and amplifying it by PCR following digestion with TspRI, gel purification and subsequent ligation with a non-telomeric coding 31-mere DNA linker. After subcloning to pML20-42 plasmid, 600 bp DNA strands contains two telomere tandem repeats of 48 bp each: (TTAGGG)8AACATCACGTACGTACGTACGTTCAAGCACT(TTAGGG)8 and non-telomere linker. The complete templates were gel purified and used for assay. To obtain the random-sequence of non-telomeric DNA templates, two single-stranded DNA fragments were synthesized and subcloned to pML20-42. One DNA fragment was [32P]- 5' end-labeled with T4 kinase. After annealing, the fragments were extended with Klenow(exo-) DNA polymerase and PCR amplified, followed by digestion with TspRI restriction enzyme and purified. To obtain the nonTelDNA for binding assays, same-length plasmid having nonTelDNA random sequence was used. For in-vitro pull-down assay, (TTAGGG)7 templates were synthesized and used either as single stranded DNA or annealed with corresponding sequences to obtain double stranded DNA. Consequently, ssDNA and dsDNA oligonucleotides of the same length with nonTelDNA random sequences have been utilized as controls. Foot-print analyses were performed as described in earlier study .
Preparation of Proteins
Recombinant full-length wild-type FANCD2 was expressed using baculovirus in Sf9 insect. The encoded FA protein contained at the amino terminus a zz domain, for purification on IgG-Sepharose. Tagged genes were cloned into a modified pFastBac vector (Invitrogen) and processed to generate recombinant baculovirus and used to infect Sf9 cells following purification and TEV cleavage procedure exactly as described earlier . TRF1 protein obtained from Dr. Chapman (MRC Laboratory of Molecular Biology, Cambridge, UK) was produced from hTRF1 expressed in E. coli following necessary purification steps. Recombinant tankyrase protein obtained from Dr. Smith was purified from the baculovirus-derived DH10Bac E. coli plasmid designed as a NH2-terminally (His)6-tagged version of human tankyrase in the expression vector pFastBac HTb (Gibco BRL) following expression in SF9 insect cells exactly as described before .
Electrophoretic mobility shift assay (EMSA)
EMSA was performed as described in Promega protocol (http://www.promega.com/guides/protein.interactions_guide/chap7.pdf). Briefly, aliquots of FANCD2 recombinant protein or cell extracts were incubated with the DNA sequence that has been P32-labeled and the DNA:protein complexes, with or without competitors (protein or specific antibody) were run on a non-denaturing polyacrylamide gel. After electrophoresis, the experimental reaction was compared to a control reaction that contains only the labeled DNA or to the signals of corresponding immunoblot done in parallel.
Immunoprecipitation and Western blot
For Western blot procedure cell lysates were eluted by boiling in SDS gel sample buffer and proteins were separated by SDS-PAGE and immunoblotted onto nylon membrane following incubation with corresponding antibodies. Protein bands were visualized with anti-rabbit or anti-mouse IgG coupled to horseradish peroxidase using the ECL kit (Amersham, Arlington Heights, IL, USA).
In vitro binding and pull-down assay
For his pull-down assays, 5 ug of tankyrase 1 fusion protein was incubated for 1 h at 4°C with Co-sepharose (Pharmacia) in TNE buffer (10 mM Tris-HCl [pH 7.8], 1% Nonidet P-40 [NP-40], 150 mM NaCl, and 1 mM EDTA). Recombinant or heat inactivated (HI) FANCD2 (both at 5 ug) was added to the binding mixture either alone or in the presence of single- or double-stranded 42 bp DNA oligonucleotides following incubation in TNE buffer for 30 min at 4°C. The beads were washed with TNE buffer 3 times and corresponding aliquots were subjected to Western blot analyses as described above (fractions W1-3). Elution was done with immidazole (0.01-0.5 M). Corresponding fractions (E1-5) were collected and analysed by Western blot as above. For measurement of protein retention, scanned Western blots were analyzed by densitometry program (Totalab2.0) and the percentage of retained proteins in elution fractions was calculated by comparing the signals from input fractions (2.5 ug of each protein).
Modified PARP activity assays were done with baculovirus-derived TNKS1 essentially as described before [28, 47]. Shortly, (His)6-tagged version of human tankyrase samples (3 ug) and/or FANCD2 (0, 0.5, 3 or 8 ug) were incubated for 30 min at 25°C in PARP buffer 50 ul of buffer containing 50 mM tris-HCl (pH 8.0), 4 mM MgCl2, 0.2 mM dithiothreitol (DTT), 1.3. M [32P]NAD+ (4 uCi). Reactions were stopped by addition of 20% trichloroacetic acid (TCA). Acid-insoluble proteins were collected by centrifugation, rinsed in 5% TCA, suspended in Laemmli loading buffer, and fractionated by SDS-polyacrylamide gel electrophoresis (4-20% SDS-PAGE). Proteins were visualized by Western blotting with corresponding antibodies and/or autoradiography of the membranes. As controls, myeling or heat-inactivated FANCD2 (obtained by boiling FANCD2 samples for 20 min) were used. PARP inhibitor 3AB was added where needed.
We are grateful to Dr. Susan Smith (The Kimmel Center for Biology and Medicine of the Skirball Institute, New York University School of Medicine) for providing us with recombinant tankyrase 1, Dr. Giraud-Panis (CNRS, Lyon), Dr. Chapman (MRC Laboratory of Molecular Biology, Cambridge, UK) for sharing materials. We would like to thank Dr. Eric Gilson (Ecole Normale Superieure de Lyon, France) for valuable comments. This work was supported by the Generalitat de Catalunya (SGR0489-2009), the La Caixa Fundation Oncology Program (BM05-67-0), Genoma Espana, the Spanish Ministry of Science and Innovation (projects FIS PI06-1099, CIBER-ER CB06/07/0023, SAF2006-3440 and SAF2009-11936), the Commission of the European Union (project RISC-RAD FI6R-CT-2003-508842), and the European Regional Development Funds. JPD laboratory is funded by the National Institutes of Health grant CA090281.
- Gurtan AM, D'Andrea AD: Dedicated to the core: understanding the Fanconi anemia complex. DNA Repair (Amst). 2006, 5: 1119-1125. 10.1016/j.dnarep.2006.05.009.View ArticleGoogle Scholar
- Mathew CG: Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006, 25: 5875-5884. 10.1038/sj.onc.1209878.View ArticlePubMedGoogle Scholar
- Taniguchi T, D'Andrea AD: Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006, 107: 4223-4233. 10.1182/blood-2005-10-4240.View ArticlePubMedGoogle Scholar
- Wang RC, Smogorzewska A, de Lange T: Homologous recombination generates T-loop-sized deletions at human telomeres. Cell. 2004, 119: 355-368. 10.1016/j.cell.2004.10.011.View ArticlePubMedGoogle Scholar
- Wang W: Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007, 8: 735-748. 10.1038/nrg2159.View ArticlePubMedGoogle Scholar
- Patel KJ, Joenje H: Fanconi anemia and DNA replication repair. DNA Repair (Amst). 2007, 6: 885-890. 10.1016/j.dnarep.2007.02.002.View ArticleGoogle Scholar
- Moldovan GL, D'Andrea AD: How the fanconi anemia pathway guards the genome. Annu Rev Genet. 2009, 43: 223-249. 10.1146/annurev-genet-102108-134222.PubMed CentralView ArticlePubMedGoogle Scholar
- Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001, 7: 249-262. 10.1016/S1097-2765(01)00173-3.View ArticlePubMedGoogle Scholar
- Huang TT, D'Andrea AD: Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol. 2006, 7: 323-334. 10.1038/nrm1908.View ArticlePubMedGoogle Scholar
- Surralles J, Jackson SP, Jasin M, Kastan MB, West SC, Joenje H: Molecular cross talk among chromosome fragility syndromes. Genes Dev. 2004, 18: 1359-1370. 10.1101/gad.1216304.PubMed CentralView ArticlePubMedGoogle Scholar
- Callen E, Surralles J: Telomere dysfunction in genome instability syndromes. Mutat Res. 2004, 567: 85-104. 10.1016/j.mrrev.2004.06.003.View ArticlePubMedGoogle Scholar
- Dokal I: Fanconi's anaemia and related bone marrow failure syndromes. Br Med Bull. 2006, 77-78. 37-53Google Scholar
- Pang Q, Andreassen PR: Fanconi anemia proteins and endogenous stresses. Mutat Res. 2009, 668: 42-53.PubMed CentralView ArticlePubMedGoogle Scholar
- Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR: A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA. 1988, 85: 6622-6626. 10.1073/pnas.85.18.6622.PubMed CentralView ArticlePubMedGoogle Scholar
- Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T: Mammalian telomeres end in a large duplex loop. Cell. 1999, 97: 503-514. 10.1016/S0092-8674(00)80760-6.View ArticlePubMedGoogle Scholar
- Greider CW: Telomeres do D-loop-T-loop. Cell. 1999, 97: 419-422. 10.1016/S0092-8674(00)80750-3.View ArticlePubMedGoogle Scholar
- de Lange T: How telomeres solve the end-protection problem. Science. 2009, 326: 948-952. 10.1126/science.1170633.PubMed CentralView ArticlePubMedGoogle Scholar
- Blasco MA: The epigenetic regulation of mammalian telomeres. Nat Rev Genet. 2007, 8: 299-309. 10.1038/nrg2047.View ArticlePubMedGoogle Scholar
- Olovnikov AM: A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973, 41: 181-190. 10.1016/0022-5193(73)90198-7.View ArticlePubMedGoogle Scholar
- Watson JD: Origin of concatemeric T7 DNA. Nat New Biol. 1972, 239: 197-201. 10.1038/239197a0.View ArticlePubMedGoogle Scholar
- Greider CW, Blackburn EH: The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell. 1987, 51: 887-898. 10.1016/0092-8674(87)90576-9.View ArticlePubMedGoogle Scholar
- Muntoni A, Reddel RR: The first molecular details of ALT in human tumor cells. Hum Mol Genet. 2005, 14: R191-196. 10.1093/hmg/ddi266.View ArticlePubMedGoogle Scholar
- De Lange T: Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol. 2005, 70: 197-204. 10.1101/sqb.2005.70.032.View ArticlePubMedGoogle Scholar
- Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA, Reddel RR: DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol. 2009, 27: 1181-1185. 10.1038/nbt.1587.View ArticlePubMedGoogle Scholar
- Xin H, Liu D, Wan M, Safari A, Kim H, Sun W, O'Connor MS, Songyang Z: TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature. 2007, 445: 559-562. 10.1038/nature05469.View ArticlePubMedGoogle Scholar
- Kim SH, Kaminker P, Campisi J: TIN2, a new regulator of telomere length in human cells. Nat Genet. 1999, 23: 405-412. 10.1038/70508.View ArticlePubMedGoogle Scholar
- Smith S, de Lange T: Tankyrase promotes telomere elongation in human cells. Curr Biol. 2000, 10: 1299-1302. 10.1016/S0960-9822(00)00752-1.View ArticlePubMedGoogle Scholar
- Smith S, Giriat I, Schmitt A, de Lange T: Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science. 1998, 282: 1484-1487. 10.1126/science.282.5393.1484.View ArticlePubMedGoogle Scholar
- Loayza D, De Lange T: POT1 as a terminal transducer of TRF1 telomere length control. Nature. 2003, 423: 1013-1018. 10.1038/nature01688.View ArticlePubMedGoogle Scholar
- Callen E, Samper E, Ramirez MJ, Creus A, Marcos R, Ortega JJ, Olive T, Badell I, Blasco MA, Surralles J: Breaks at telomeres and TRF2-independent end fusions in Fanconi anemia. Hum Mol Genet. 2002, 11: 439-444. 10.1093/hmg/11.4.439.View ArticlePubMedGoogle Scholar
- Verdun RE, Karlseder J: Replication and protection of telomeres. Nature. 2007, 447: 924-931. 10.1038/nature05976.View ArticlePubMedGoogle Scholar
- Park WH, Margossian S, Horwitz AA, Simons AM, D'Andrea AD, Parvin JD: Direct DNA binding activity of the Fanconi anemia D2 protein. J Biol Chem. 2005, 280: 23593-23598. 10.1074/jbc.M503730200.View ArticlePubMedGoogle Scholar
- Spardy N, Duensing A, Hoskins EE, Wells SI, Duensing S: HPV-16 E7 reveals a link between DNA replication stress, fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies. Cancer Res. 2008, 68: 9954-63. 10.1158/0008-5472.CAN-08-0224.PubMed CentralView ArticlePubMedGoogle Scholar
- Fan Q, Zhang F, Barrett B, Ren K, Andreassen PR: A role for monoubiquitinated FANCD2 at telomeres in ALT cells. Nucleic Acids Res. 2009, 37: 1740-1754. 10.1093/nar/gkn995.PubMed CentralView ArticlePubMedGoogle Scholar
- Chang W, Dynek JN, Smith S: TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres. Genes Dev. 2003, 17: 1328-1333. 10.1101/gad.1077103.PubMed CentralView ArticlePubMedGoogle Scholar
- Muramatsu Y, Tahara H, Ono T, Tsuruo T, Seimiya H: Telomere elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ation. Exp Cell Res. 2008, 314: 1115-1124. 10.1016/j.yexcr.2007.12.005.View ArticlePubMedGoogle Scholar
- Cook BD, Dynek JN, Chang W, Shostak G, Smith S: Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol Cell Biol. 2002, 22: 332-342. 10.1128/MCB.22.1.332-342.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Leteurtre F, Li X, Guardiola P, Le Roux G, Sergere JC, Richard P, Carosella ED, Gluckman E: Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J Haematol. 1999, 105: 883-893. 10.1046/j.1365-2141.1999.01445.x.View ArticlePubMedGoogle Scholar
- Pickett HA, Cesare AJ, Johnston RL, Neumann AA, Reddel RR: Control of telomere length by a trimming mechanism that involves generation of t-circles. EMBO J. 2009, 28: 799-809. 10.1038/emboj.2009.42.PubMed CentralView ArticlePubMedGoogle Scholar
- Hanson H, Mathew CG, Docherty Mackie Z, Ogilvie C: Telomere shortening in Fanconi anaemia demonstrated by a direct FISH approach. Cytogenet Cell Genet. 2001, 93: 203-206. 10.1159/000056985.View ArticlePubMedGoogle Scholar
- Cabuy E, Newton C, Joksic G, Woodbine L, Koller B, Jeggo PA, Slijepcevic P: Accelerated telomere shortening and telomere abnormalities in radiosensitive cell lines. Radiat Res. 2005, 164: 53-62. 10.1667/RR3376.View ArticlePubMedGoogle Scholar
- Li X, Leteurtre F, Rocha V, Guardiola P, Berger R, Daniel MT, Noguera MH, Maarek O, Roux GL, de la Salmonière P, Richard P, Gluckman E: Abnormal telomere metabolism in Fanconi's anaemia correlates with genomic instability and the probability of developing severe aplastic anaemia. Br J Haematol. 2003, 120: 836-45. 10.1046/j.1365-2141.2003.04225.x.View ArticlePubMedGoogle Scholar
- Lyakhovich A, Surrallés J: Constitutive activation of caspase-3 and Poly ADP ribose polymerase cleavage in fanconi anemia cells. Mol Cancer Res. 2010, 8: 46-56. 10.1158/1541-7786.MCR-09-0373.View ArticlePubMedGoogle Scholar
- Amiard S, Doudeau M, Pinte S, Poulet A, Lenain C, Faivre-Moskalenko C, Angelov D, Hug N, Vindigni A, Bouvet P, Paoletti J, Gilson E, Giraud-Panis MJ: A topological mechanism for TRF2-enhanced strand invasion. Nat Struct Mol Biol. 2007, 14: 147-154. 10.1038/nsmb1192.View ArticlePubMedGoogle Scholar
- Bogliolo M, Lyakhovich A, Callen E, Castella M, Cappelli E, Ramirez MJ, Creus A, Marcos R, Kalb R, Neveling K, Schindler D, Surralles J: Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J. 2007, 26: 1340-1351. 10.1038/sj.emboj.7601574.PubMed CentralView ArticlePubMedGoogle Scholar
- Driscoll MD, Klinge CM, Hilf R, Bambara RA: Footprint analysis of estrogen receptor binding to adjacent estrogen response elements. J Steroid Biochem Mol Biol. 1996, 58: 45-61. 10.1016/0960-0760(96)00015-5.View ArticlePubMedGoogle Scholar
- Simonin F, Poch O, Delarue M, de Murcia G: Identification of potential active-site residues in the human poly(ADP-ribose) polymerase. J Biol Chem. 1993, 268: 8529-8535.PubMedGoogle Scholar
- Slijepcevic P: Telomere length measurement by Q-FISH. Methods Cell Sci. 2001, 23: 17-22. 10.1023/A:1013177128297.View ArticlePubMedGoogle Scholar
- Baerlocher GM, Vulto I, de Jong G, Lansdorp PM: Flow cytometry and FISH to measure the average length of telomeres. Nature Protocols. 2006, 1: 2365-2376. 10.1038/nprot.2006.263.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.